Skip to main content
SpringerLink
Log in

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The efficacy and safety of the HMG CoA reductase inhibitor fluvastatin have been evaluated in a double blind study in 52 patients with familial hypercholesterolaemia. A standard AHA Phase II lipid lowering diet was prescribed throughout the study. After 6 weeks of a single blind dosage stabilisation period, in which patients received fluvastatin 40 mg qPM, patients were randomly allocated to one of two double blind treatment groups: group A (n=24) received fluvastatin 20 mg b. d. for 12 weeks and fluvastatin 20 mg AM + 40 mg PM for an additional 12 weeks; Group B (n=28) received fluvastatin 40 mg qPM during the entire study. Safety and tolerability were evaluated by the analysis of biochemical and haematological parameters, and ophthalmological and physical examinations. Efficacy was analysed by the determination of plasma lipids, lipoproteins and apoproteins.

Fluvastatin 40 mg/d was associated with up to a 27.4% decrease in LDL-C and a 9.6% increase in HDL-C concentrations. Increasing the dose of fluvastatin from 20 mg b. d. to 60 mg per day in Group A was associated with a 7.1% decrease in LDL-C, a 12.1% increase of HDL-C and a 12.8% decrease in the LDL-C/HDL-C ratio. In comparison with Group B (40 mg qPM) LDL-C, HDL-C and the LDL-C/HDL-C ratio in Group A (60 mg) differed by −8.9%, 6.6% and −12%, respectively. During treatment with 40 mg qPM, one patient developed an asymptomatic but notable elevation of CK to 1823 U/l (normal range 0–100 U/l) that was caused by strenuous exercise. No other notable biochemical or haematological abnormalities were recorded.

It is concluded that in patients with heterozygous FH the increase of fluvastatin from 40 to 60 mg/d provided an additional significant effect on plasma LDL-C and HDL-C levels and in the LDL-C/HDL-C ratio, without producing any deleterious effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldstein JL, Brown MS (1989) Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease, 6th edn. McGraw-Hill, New York, pp 1215–1250

    Google Scholar 

  2. Hobbs HH, Russell DW, Brown MS, Goldstein JL (1990) The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Ann Rev Genet 24: 133–170

    Google Scholar 

  3. Oppenheim A, Friedlander Y, Dann EJ, Berkman N, Pressman Schwartz S, Leitersdorf E (1991) Hypercholesterolemia in five Israeli Christian-Arab kindreds is caused by the “Lebanese” allele at the LDL receptor gene locus as well as by an additional independent major factor. Hum Genetics 88: 75–84

    Google Scholar 

  4. Meiner V, Landsberger D, Berkman N, Reshef A, Segal P, Seftel HC, van der Westhuyzen DR, Jeenah MS, Coetzee GA, Leitersdorf E (1991) A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet 49: 443–449

    Google Scholar 

  5. Landsberger D, Meiner V, Reshef A, Levy Y, van der Westhuyzen DR, Coetzee GA, Leitersdorf E (1992) A nonsense mutation in the LDL receptor gene leads to familial hypercholesterolemia in the Druze Sect. Am J Hum Genet 50: 427–433

    Google Scholar 

  6. Leitersdorf E, Reshef A, Meiner V, Dann EJ, Beigel Y, van Roggen FG, van der Westhuyzen DR, Coetzee GA (1993) A missense mutation in the low density lipoprotein receptor gene causes familial hypercholesterolemia in Sephardic Jews. Hum Genet 91: 141–147

    Google Scholar 

  7. Berkman N, Weir BS, Pressman Schwartz S, Reshef A, Leitersdorf E (1992) Haplotype analysis at the low density lipoprotein receptor locus: application for the analysis of familial hypercholesterolemia in Israel. Hum Genetics 88: 405–410

    Google Scholar 

  8. Grundy SM, Vega GL, Bilheimer DW (1985) Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med 103(3) 339–343

    Google Scholar 

  9. Illingworth DR, Bacon S (1989) Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 79: 590–596

    Google Scholar 

  10. Witztum JL, Simmons D, Steinberg D, Beltz WF, Weinreb R, Young SG, Lester P, Kelly N, Juliano J (1989) Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation 79: 16–28

    Google Scholar 

  11. Wiklund O, Angelin B, Fager G, Eriksson M, Olfosson SO, Berglund L (1990) Treatment of familial hypercholesterolemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Int Med 228(3) 241–247

    Google Scholar 

  12. Ditschuneit HH, Kuhn K, Ditschuneit H (1991) Comparison of different HMG CoA reductase inhibitors. Eur J Clin Pharmacol 40 [Suppl 1]: S27-S32

    Google Scholar 

  13. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M, Bard JM, Fruchart JC, Stein Y (1993) Differential response of plasma cholesterol to fluvastatin, a new HMG CoA reductase inhibitor, in three groups of genetically defined heterozygote patients with familial hypercholesterolemia. Circulation 87 [Suppl III]: III35-III44

    Google Scholar 

  14. Raveh D, Israeli A, Arnon R, Eisenberg S (1990) Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. Atherosclerosis 82: 19–26

    Google Scholar 

  15. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502

    Google Scholar 

  16. Henwood JM, Heel RC (1988) Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs 36: 429–454

    Google Scholar 

  17. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL (1989) HMG CoA reductase inhibitors lower LDL-cholesterol without reducing Lp(a) levels. Circulation 80: 1313–1319

    Google Scholar 

  18. Utermann G (1989) The mysteries of lipoprotein(a). Science 246: 904–910

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medicine and The Center for Research Prevention and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel

    E. Leitersdorf, S. Eisenberg, O. Eliav, N. Berkman, E. J. Dann, D. Landsberger, E. Sehayek, V. Meiner & Y. Stein

  2. Cardiovascular Department, Clinical Research, Sandoz Pharma Ltd., Basel, Switzerland

    T. K. Peters & E. N. Muratti

  3. Service de Recherches sur les Lipoprotéines et l'Athérosclérose et INSERM U325, Institut Pasteur, Lille, France

    J. -M. Bard & J. -C. Fruchart

Authors
  1. E. Leitersdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Eisenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Eliav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Berkman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. J. Dann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Landsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Sehayek
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. Meiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. K. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. N. Muratti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. -M. Bard
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. -C. Fruchart
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Y. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leitersdorf, E., Eisenberg, S., Eliav, O. et al. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia. Eur J Clin Pharmacol 45, 513–518 (1993). https://doi.org/10.1007/BF00315307

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315307

Key words

Search

Navigation